Group sequential trials, interim analyses, final analyses, updated analyses… what do these terms actually mean, and why is there so much confusion?
In this technical yet highly practical episode, I speak with Kaspar Rufibach, Principal Biostatistician at Roche, to unpack some of the most commonly misunderstood terminology and concepts in clinical trial design and analysis.
If you’ve ever questioned what really qualifies as an “interim analysis” or struggled to explain why a “final analysis” isn’t always the last word, this conversation is for you.
What You’ll Learn in This Episode:
Dr. Alexander Schacht
Group sequential trials, interim analyses, final analyses, updated analyses… what do these terms actually mean, and why is there so much confusion?
In this technical yet highly practical episode, I speak with Kaspar Rufibach, Principal Biostatistician at Roche, to unpack some of the most commonly misunderstood terminology and concepts in clinical trial design and analysis.
If you’ve ever questioned what really qualifies as an “interim analysis” or struggled to explain why a “final analysis” isn’t always the last word, this conversation is for you.
What You’ll Learn in This Episode:
Clarifying confusions around interim, primary, final, and other analyses in clinical trial
Dr. Alexander Schacht
Group sequential trials, interim analyses, final analyses, updated analyses… what do these terms actually mean, and why is there so much confusion?
In this technical yet highly practical episode, I speak with Kaspar Rufibach, Principal Biostatistician at Roche, to unpack some of the most commonly misunderstood terminology and concepts in clinical trial design and analysis.
If you’ve ever questioned what really qualifies as an “interim analysis” or struggled to explain why a “final analysis” isn’t always the last word, this conversation is for you.